Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.6052W HIGH $8.48
Volume
397.04 K
Value Traded
3.23 M
Short % Float
27.95%
-6.39%Week
-17.35%1 Month
-25.44%3 Month
-30.98%6 Month
-72.36%5 Year
-72.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
248.11 M
EPS (TTM)
-0.89
P/E Ratio
-
Ent. Value
65.44 M
Total Shares
64.66 M
Float Shares
55.63 M
Insiders
14.02%
Institutions
54.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IMRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Immuneering Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immuneering Corporation
152Total events
21Upcoming
30Tier-1 (high impact)
2021 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Poster PresentationAtebimetinibPresentation
Poster presented at 2026 AACR Conference on Pancreatic Cancer on atebimetinib dual mechanism in pancreatic cancer
first-line pancreatic cancersource ↗
▲Additional DataAtebimetinibClinical Data
New exploratory analyses of atebimetinib + mGnP Phase 2a data: weight preservation and tumor volume reduction vs overall survival
first-line pancreatic cancersource ↗
◆AbstractAtebimetinibPresentation
Abstract for atebimetinib AACR pancreatic cancer poster to be available on AACR website
pancreatic cancersource ↗
▲FDA ApprovalFDA Decision
FDA approval of a new treatment for second-line metastatic pancreatic cancer
second-line metastatic pancreatic cancersource ↗
●Trial InitiationAtebimetinibTrial
MAPKeeper 301 trial enrolling patients
first-line metastatic pancreatic cancersource ↗
▲First Patient DosedAtebimetinibTrial
First patient dosed in Phase 2 trial of atebimetinib + Libtayo in NSCLC
RAS-mutant first-line non-small cell lung cancersource ↗
▲PublicationAtebimetinibPresentation
Publication in Cancer Research detailing atebimetinib's preclinical activity
RAS- and RAF-mutant tumorssource ↗
◆Trial InitiationAtebimetinibTrial
Dose first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in NSCLC
non-small cell lung cancersource ↗
▲First Patient DosedAtebimetinibTrial
First patient dosed in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer
first-line metastatic pancreatic cancersource ↗
◆Trial InitiationAtebimetinibTrial
Phase 3 trial of atebimetinib in first-line pancreatic cancer expected to begin dosing
first-line pancreatic cancersource ↗
▲First Patient DosedAtebimetinibTrial
First patient dosed in Phase 3 MAPKeeper 301 trial
first-line metastatic pancreatic cancersource ↗
▲Oral PresentationAtebimetinibPresentation
Oral presentation of Phase 2a data at ASCO 2026 Annual Meeting
first-line pancreatic cancersource ↗
▲Topline ReadoutAtebimetinibClinical Data
17.3 months median overall survival reported in Phase 2a trial of atebimetinib plus mGnP
first-line metastatic pancreatic cancersource ↗
▲Full ResultsAtebimetinibClinical Data
Phase 2a study results reported: 17.3 months median overall survival
first-line metastatic pancreatic cancersource ↗
◆Poster PresentationAtebimetinibPresentation
AACR 2026 poster presentation on atebimetinib's Deep Cyclic Inhibition constraining MAPK-axis alterations
RAS-mutant tumorssource ↗
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
▲First Patient DosedAtebimetinibTrial
Dose first patient in pivotal Phase 3 trial MAPKeeper 301
first-line pancreatic cancersource ↗
◆Trial InitiationAtebimetinibTrial
Phase 3 trial expected to begin dosing in mid-2026
first-line pancreatic cancersource ↗
◆Oral PresentationAtebimetinibPresentation
Oral presentation at AACR 2026
RAS- and RAF-mutant tumorssource ↗
▲Poster PresentationAtebimetinibPresentation
Poster presentation at AACR with genetic data from atebimetinib-treated patients
pancreatic cancersource ↗
◆Oral PresentationPresentation
Immuneering management to present at Leerink Global Healthcare Conference
◆Oral PresentationPresentation
Immuneering to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
◆Oral PresentationAtebimetinibPresentation
12-month overall survival data update from Phase 2a trial of atebimetinib + mGnP
first-line pancreatic cancersource ↗
▲Full ResultsAtebimetinibClinical Data
Reported 64% OS at 12 months in Phase 2a trial of atebimetinib + mGnP
first-line pancreatic cancersource ↗
▲Full ResultsAtebimetinibClinical Data
Reported 64% overall survival at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP
first-line pancreatic cancersource ↗
▲Topline ReadoutAtebimetinibClinical Data
17.3-month median overall survival reported at ASCO 2026 in 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP
first-line pancreatic cancersource ↗
▲End Of Phase 2 MeetingAtebimetinibFDA Meeting
End-of-Phase 2 interactions with FDA completed
first-line metastatic pancreatic cancersource ↗
▲EU MAA SubmissionAtebimetinibEx-US Regulatory
Scientific advice received from EMA
first-line metastatic pancreatic cancersource ↗
▲End Of Phase 2 MeetingAtebimetinibFDA Meeting
Completed End-of-Phase 2 interactions with FDA and received scientific advice from EMA
first-line metastatic pancreatic cancersource ↗
▲Full ResultsAtebimetinibClinical Data
New reports of first-line pancreatic cancer patients with excellent responses to atebimetinib + FOLFIRINOX, including a complete response and a patient able to pursue radiation and surgery with curative intent
first-line pancreatic cancersource ↗
◆FDA Feedback ReceivedAtebimetinibFDA Meeting
Regulatory feedback on pivotal study plans
first-line pancreatic cancersource ↗
◆Oral PresentationAtebimetinibPresentation
Conference call and webcast to discuss updated overall survival and safety data
first-line pancreatic cancersource ↗
◆Oral PresentationAtebimetinibPresentation
Presentation at PanCAN Annual Scientific Summit
first-line pancreatic cancersource ↗
◆Poster PresentationAtebimetinibPresentation
Poster presentation of updated overall survival and safety data at PanCAN Scientific Summit 2025
first-line pancreatic cancersource ↗
▼Equity OfferingCorporate
Concurrent $25 million private placement of Class A common stock to Sanofi
◆Oral PresentationAtebimetinibPresentation
Updated data with 9 months median follow up from phase 2a study of atebimetinib + mGnP
first-line pancreatic cancersource ↗
▼Equity OfferingCorporate
Proposed underwritten public offering of Class A common stock and pre-funded warrants
▲Partnership / LicenseCorporate
Sanofi agrees to purchase $25.0 million of shares in concurrent private placement
◆Topline ReadoutAtebimetinibClinical Data
Updated overall survival and safety data announced
first-line pancreatic cancersource ↗
▲Full ResultsAtebimetinibClinical Data
Announced 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP
first-line pancreatic cancersource ↗
▲Equity OfferingCorporate
Raised $225 million of financing, including $25 million private placement with Sanofi
Past FDA Catalysts and PDUFA Decisions
How IMRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-07 | atebimetinib | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$95M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.4x
rNPV / MCap
Top 65%
Micro Cap(rank 428 of 658)
Percentile Rank
Immuneering Corporation faces pipeline headwinds (31/100), with $380M risk-adjusted pipeline value, led by Atebimetinib in Advanced Solid Tumor (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Atebimetinib Small moleculeNCT07562152 | Pancreatic Cancer | Phase 3 | RECRUITING | 510 | Feb 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| atebimetinib | pancreatic cancer | Phase 2a | 2026-09-28 | 84% of evaluable patients treated with atebimetinib + mGnP have stable or increasing weight; patients in our study were twice as likely to have stable or increasing weight as those in a benchmark study; patients who maintained their weight at three months had longer overall survival than those who lost weight; 17.3-month median overall survivalRead More | Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gengos AndrewOfficer (Chief Financial Officer) | Grant/Award | 650,000 650,000 held | $0.00 | 07/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0 % (-100 %) | 183.00 K | 36.86 K | -70.13% ( -86.55 K) |
IMRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMRX ranks across every disease it competes in
Competitive Position is a premium feature
See how IMRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMRX News
IMRXImmuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Immuneering Corporation announced it will present findings at the 41st Annual Meeting of the Society for Immunotherapy of Cancer. The research indicates that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumors, supporting a Phase 2 study in lung cancer patients. The presentation is scheduled for November 6, 2026, in Phoenix, AZ.
Read more →IMRXImmuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Immuneering Corporation presented promising data at the 2026 AACR Conference regarding atebimetinib's potential to improve survival in pancreatic cancer patients. The study indicated that patients receiving atebimetinib in combination with mGnP had better weight stability and overall survival compared to benchmark studies. The findings support a dual mechanism of action aimed at tumor volume reduction and body mass preservation. The ongoing Phase 3 MAPKeeper 301 trial will further explore these effects.
Read more →IMRXImmuneering to Present at the ESMO Congress 2026
Immuneering Corporation announced that its Phase 3 MAPKeeper 301 trial abstract has been accepted for poster presentation at the ESMO Congress 2026. The trial evaluates atebimetinib combined with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer treatment. The presentation is scheduled for October 25, 2026, in Madrid, Spain.
Read more →IMRXImmuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Immuneering Corporation will present findings on atebimetinib at the AACR Conference, emphasizing its dual mechanism of reducing tumor volume and preserving body mass in pancreatic cancer patients. The data indicates that 84% of evaluable patients maintained or gained weight after three months of treatment. The presentation aims to highlight the potential for improved overall survival.
Read more →IMRXImmuneering to Participate in Upcoming Investor Conferences
Immuneering Corporation announced its participation in two upcoming investor conferences in New York City. The Cantor Global Healthcare Conference will take place from September 9-11, with Immuneering's presentation scheduled for September 10. Additionally, the H.C. Wainwright 28th Annual Global Investment Conference is set for September 14-16, featuring another presentation on September 14. The company aims to highlight its innovative cancer treatments.
Read more →IMRXImmuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Immuneering Corporation commented on the recent FDA approval of a new treatment for second-line metastatic pancreatic cancer, highlighting its focus on first-line patients. The company is conducting a Phase 3 trial, MAPKeeper 301, for its drug atebimetinib, which previously showed a median overall survival of 17.3 months in a Phase 2a study. CEO Ben Zeskind emphasized the importance of developing effective treatments for first-line patients while managing side effects.
Read more →IMRXImmuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Immuneering Corporation reported its Q2 2026 financial results, highlighting a median overall survival of 17.3 months for first-line pancreatic cancer patients treated with atebimetinib. The company is currently conducting the Phase 3 MAPKeeper 301 trial and has a strong cash position expected to last until 2029. Recent publications support atebimetinib's efficacy and tolerability, while the company also appointed a new CFO.
Read more →IMRXPublication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
Atebimetinib has shown significant antitumor activity in preclinical studies targeting KRAS, NRAS, and BRAF mutations. The drug effectively inhibits RAF-mediated bypass signaling, which has limited the effectiveness of other MEK inhibitors. Its favorable tolerability profile was also noted, making it a promising candidate for further development in treating various cancers.
Read more →IMRX▼ -7.5%on this newsshared move
Immuneering Corporation Announces Grants of Inducement Awards
Immuneering Corporation has announced the granting of inducement awards to new employees, including a significant stock option for newly appointed CFO Andrew Gengos. The options are part of the company's strategy to attract talent while focusing on developing innovative cancer therapies. The company is currently conducting pivotal trials for its lead product candidate, atebimetinib.
Read more →IMRXImmuneering Appoints Andrew Gengos as Chief Financial Officer
Immuneering Corporation has appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos, previously CFO at Terns Pharmaceuticals, will oversee financial strategy and corporate development as the company progresses its lead oncology candidate, atebimetinib, currently in Phase 3 trials for pancreatic cancer. His extensive experience in biotech is expected to enhance Immuneering's growth.
Read more →IMRX▲ +5.1%on this newsshared move
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Corporation has announced that the first patient has been dosed in the MAPKeeper 301 pivotal Phase 3 trial, which studies the combination of atebimetinib and modified gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The trial aims to demonstrate the efficacy and safety of this new treatment regimen compared to standard therapy. Overall survival is the primary endpoint, with additional metrics being evaluated, and topline data is expected to be available in mid-2028.
Read more →IMRX▼ -22.1%on this newsshared move
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Corporation presented promising data from its Phase 2a trial showing an impressive median overall survival of 17.3 months in 55 first-line pancreatic cancer patients treated with atebimetinib combined with chemotherapy. This outcome notably exceeds the historical median of 8.5 months reported in the standard of care chemotherapy. The trial exhibited only limited severe adverse events and a favorable tolerability profile, with a high percentage of participants maintaining or gaining weight. The ongoing recruitment for the Phase 3 MAPKeeper 301 trial aims to further evaluate atebimetinib's effectiveness in this patient population.
Read more →IMRXImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Corporation reported a 17.3-month median overall survival for first-line metastatic pancreatic cancer patients treated with atebimetinib plus chemotherapy in a Phase 2a trial. The trial included 55 patients, with a tolerability profile consistent with prior updates. The company plans to present detailed findings at the ASCO Annual Meeting on June 1, 2026, and is currently recruiting for a pivotal Phase 3 trial.
Read more →IMRXImmuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be pres
Immuneering Corporation has reported positive financial results for Q1 2026, showcasing new survival data from its Phase 2a clinical trial of atebimetinib in first-line metastatic pancreatic cancer set to be presented at the upcoming ASCO Annual Meeting. The company's pivotal Phase 3 MAPKeeper 301 trial is actively recruiting patients, with expectations to dose the first participant by mid-2026. Amid an overall cash position of $198.6 million, which is projected to sustain operations until 2029, Immuneering's developments suggest strong potential in improving treatment outcomes for pancreatic cancer patients.
Read more →IMRXImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Corporation announced that new survival data from its Phase 2a clinical trial of atebimetinib combined with mGnP in first-line pancreatic cancer patients will be presented at the 2026 ASCO Annual Meeting. The presentation will include data from an expanded cohort of 55 patients, highlighting the treatment's potential to positively impact survival rates. Immuneering aims to showcase the efficacy of atebimetinib, which is designed to shrink tumors while preserving body mass and ensuring tolerability. This oral presentation marks a key moment for the company as it continues to develop innovative cancer treatments.
Read more →IMRXImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Immuneering Corporation presented new genetic data at the 2026 AACR Annual Meeting, highlighting the potential of their drug, atebimetinib, in improving survival for pancreatic cancer patients. The findings indicate that atebimetinib-treated tumors show rare mutations associated with drug resistance, suggesting that it may provide more durable treatment efficacy compared to conventional therapies. The company is expected to initiate a pivotal Phase 3 trial of atebimetinib in combination with chemotherapy in mid-2026, further supporting the drug's promising profile in oncology.
Read more →IMRXImmuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering Corporation announced that CEO Ben Zeskind will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The company is focused on developing Deep Cyclic Inhibitors, with its lead candidate, atebimetinib, targeting various cancer indications. The pivotal Phase 3 trial for atebimetinib is expected to begin mid-2026.
Read more →IMRXImmuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering Corporation announced it will present data on atebimetinib at the AACR Annual Meeting in April 2026. The presentation will focus on the drug's ability to shrink tumors durably and mitigate resistance mechanisms in RAS-mutant solid tumors. The findings suggest that atebimetinib may provide a more sustained clinical benefit compared to conventional MAPK inhibitors.
Read more →IMRX▲ +7%on this news
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering Corporation reported strong financial results for the fourth quarter and full year 2025, highlighting a 64% overall survival rate in its Phase 2a trial of atebimetinib combined with mGnP in pancreatic cancer patients. The company plans to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026 after securing FDA and EMA alignment. Despite a substantial cash position and upcoming clinical milestones, Immuneering continues to experience financial losses and rising administrative costs. Nevertheless, their drug candidate, atebimetinib, shows promise in improving overall survival through innovative mechanisms.
Read more →IMRXImmuneering to Present at the Leerink Global Healthcare Conference
Immuneering Corporation will present at the Leerink Global Healthcare Conference on March 9-11, 2026, in Miami. CEO Ben Zeskind will discuss the company's pipeline and business strategy. Immuneering focuses on developing Deep Cyclic Inhibitors to enhance cancer patient survival. The lead candidate, atebimetinib, targets MAPK pathway-driven tumors and is set for a pivotal Phase 3 trial.
Read more →About Immuneering Corporation
Headquarters245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next IMRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime